Csikos, C.; Vágner, A.; Nagy, G.; Kálmán-Szabó, I.; Szabó, J.P.; Ngo, M.T.; Szoboszlai, Z.; Szikra, D.; Krasznai, Z.T.; Trencsényi, G.;
et al. In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model. Diagnostics 2023, 13, 236.
https://doi.org/10.3390/diagnostics13020236
AMA Style
Csikos C, Vágner A, Nagy G, Kálmán-Szabó I, Szabó JP, Ngo MT, Szoboszlai Z, Szikra D, Krasznai ZT, Trencsényi G,
et al. In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model. Diagnostics. 2023; 13(2):236.
https://doi.org/10.3390/diagnostics13020236
Chicago/Turabian Style
Csikos, Csaba, Adrienn Vágner, Gábor Nagy, Ibolya Kálmán-Szabó, Judit P. Szabó, Minh Toan Ngo, Zoltán Szoboszlai, Dezső Szikra, Zoárd Tibor Krasznai, György Trencsényi,
and et al. 2023. "In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model" Diagnostics 13, no. 2: 236.
https://doi.org/10.3390/diagnostics13020236
APA Style
Csikos, C., Vágner, A., Nagy, G., Kálmán-Szabó, I., Szabó, J. P., Ngo, M. T., Szoboszlai, Z., Szikra, D., Krasznai, Z. T., Trencsényi, G., & Garai, I.
(2023). In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model. Diagnostics, 13(2), 236.
https://doi.org/10.3390/diagnostics13020236
